文献速递神经肿瘤

脑肿瘤患者商业航空飞行的安全性:病例系列研究

Safety of commercial airflight in patients with brain tumors: a case series.
PubMed 文献 · J Neurooncol · 2018-05-17

本研究评估无严重或进行性神经功能缺损的脑及颅底肿瘤患者商业航空飞行的安全性。2014至2017年因手术飞抵本中心的63例患者中41例完成调查,10例(24.4%)飞行中出现症状加重,无永久性神经功能缺损;围飞行期使用糖皮质激素与症状加重呈负相关(p=0.048)。

要点

  • 41例完成调查的脑及颅底肿瘤患者中,10例(24.4%)飞行中出现症状加重,无永久性神经缺损。
  • 围飞行期使用糖皮质激素与症状加重呈负相关(p=0.048)。
  • 完全无症状肿瘤患者飞行中未出现新发症状。

核心结论

  • 作者认为大多数脑及颅底肿瘤患者可安全进行商业航空飞行,症状加重程度可接受;但对有症状和/或肿瘤较大伴占位效应及瘤周水肿的患者,应考虑给予糖皮质激素并可能给予抗惊厥药。

研究设计与样本

  • 病例系列研究:2014至2017年因手术经商业航空飞抵本中心的脑肿瘤患者,通过RedCap电子问卷调查飞行时长、机型、症状及围飞行期新发或加重症状,症状严重度用视觉模拟量表(VAS)评估,症状显著变化定义为大于25%。

主要发现

  • 665例脑肿瘤手术患者中63例(9.5%)乘飞机至本中心手术,其中41例(65%)完成研究(平均年龄48.5±16.8岁,63%女性)。
  • 病理包括垂体及其他鞍旁肿瘤(58%)、脑膜瘤(22%)、转移瘤(5%)、胶质瘤(5%)、松果体肿瘤(5%)、小脑桥脑角肿瘤(5%);平均肿瘤体积11.4 cc,平均最大径2.7 cm。
  • 10例(24.4%)飞行中出现症状加重:头痛3/19(15.8%)、乏力3/14(21.4%)、头晕3/5(60%)、耳痛3/3(100%),另有1例飞行中新发癫痫发作;7例(70%)在飞行后症状持续加重。
  • 无与飞行相关的永久性神经功能缺损;肿瘤大小、体积、位置及飞行时长与神经症状发生无相关性;围飞行期糖皮质激素使用与症状加重呈负相关(p=0.048)。
  • 完全无症状肿瘤患者飞行中未出现新发症状。

临床怎么用

  • 作者认为对有症状和/或肿瘤较大伴占位效应及瘤周水肿的患者,应考虑给予糖皮质激素并可能给予抗惊厥药。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patients with intracranial masses are often advised to avoid airflight due to concerns of worsening neurological symptoms or deterioration. However, many patients often travel cross-country or internationally to tertiary care centers for definitive care. This study assesses the safety of commercial airflight for brain and skull base tumor patients without severe or progressive neurological deficits. METHODS: Patients that had traveled to our institution for surgery via commercial airflight from 2014 to 2017 were identified. An electronic survey was administered (RedCap) and flight duration, aircraft type, presenting symptoms and new or worsened peri-flight symptoms were queried. Severity was assessed using visual analogue scale (VAS). Significant change of symptoms was determined to be greater than 25%. Demographics and clinical history were obtained from electronic medical records. Providence Health System IRB: 16-168. RESULTS: Of 665 patients operated on for brain tumor, 63 (9.5%) traveled by airflight to our center for surgery and of these, 41 (65%) completed the study (mean age 48.5 ± 16.8 years, 63% female). Pathology included pituitary and other parasellar tumors (58%), meningiomas (22%), metastatic tumors (5%), gliomas (5%), pineal tumor (5%), cerebello-pontine tumor (5%). Average tumor volume was 11.4 cc and average maximal dimension was 2.7 cm. Ten (24.4%) patients developed worsened symptoms during airflight including: headaches 3/19 (15.8%), fatigue 3/14 (21.4%), dizziness 3/5 (60%) and ear pain 3/3 (100%), as well as one patient who had new onset seizures inflight. Seven patients (70%) sustained worsened symptoms after airflight. There were no permanent neurological deficits related to airflight. There was no correlation with tumor size, volume, location or flight duration with development of neurological symptoms. There was an inverse correlation between peri-flight corticosteroid usage and symptom exacerbation (p = 0.048). No patient with completely asymptomatic tumors developed new symptoms during flight. CONCLUSIONS: Most patients with brain and skull base tumors can travel safely via commercial airflight with acceptable symptom exacerbation. However, consideration should be given to administering corticosteroids and possibly anticonvulsants to patients who are symptomatic and/or have relatively large tumors with mass effect and peritumoral edema.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Phillips M, Saria M, Eisenberg A, et al. Safety of commercial airflight in patients with brain tumors: a case series. J Neurooncol. 2018. PMID: 29774497. doi:10.1007/s11060-018-2905-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。